09 July 2026

CSL issues open letter as EU moves to revoke avacopan approval

3 minute read

ANCA-associated vasculitis Pharmaceuticals

CSL has urged patients taking avacopan to speak with their treating specialist after European regulators recommended revoking the drug's marketing authorisation.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Register for a new account

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

Billing Address

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...

CSL issues open letter as EU moves to revoke avacopan approval

Those bacteria all look the same, don’t they?

Butler vows to get GLP-1s on PBS, ‘one way or the other’

ME/CFS returns to the Australian Burden of Disease Study

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Log in

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover